16:12:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-22 Kvartalsrapport 2024-Q1
2024-05-02 X-dag ordinarie utdelning ACOU 0.00 SEK
2024-04-30 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-07 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-04-26 X-dag ordinarie utdelning ACOU 0.00 SEK
2023-04-25 Årsstämma 2023
2023-02-22 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-28 X-dag ordinarie utdelning ACOU 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-12-21 Extra Bolagsstämma 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-15 X-dag ordinarie utdelning ACOU 0.00 SEK
2021-02-24 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-10 X-dag ordinarie utdelning ACOU 0.00 SEK
2020-06-09 Årsstämma 2020
2020-05-27 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2019-11-20 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-06-18 X-dag ordinarie utdelning ACOU 0.00 SEK
2019-06-17 Årsstämma 2019
2019-05-22 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-06-14 X-dag ordinarie utdelning ACOU 0.00 SEK
2018-06-13 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-03-21 Extra Bolagsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-11-24 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-06-19 X-dag ordinarie utdelning ACOU 0.00 SEK
2017-06-16 Årsstämma 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-11-25 Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
AcouSort är verksamt inom medicinteknik. Idag har bolaget en utvecklad plattformsteknologi inriktad mot akustofores, som med hjälp utav ultraljud separerar och analyserar biologiska cellers sammansättningar. Tekniken används huvudsakligen vid analys av cancerfall och sepsis (blodförgiftning). En stor del av forskningen sker i samarbete med övriga aktörer inom Life-Science. Bolaget etablerades under 2010 och har sitt huvudkontor i Lund.
2024-05-24 09:45:00

AcouSort has been selected by the European Innovation Council (EIC) for participation in the European Pavilion at BIO 2024 in San Diego, USA, after a competitive evaluation process. AcouSort is thereby one of only 15 European companies selected by the EU for full sponsorship at America’s leading medical trade fair, taking place in San Diego June 3-6. AcouSort has also been invited to participate in ISCT in Vancouver where the company will showcase its innovative solutions.

During the convention in San Diego, AcouSort will mainly focus on partnering and 1-on-1 meetings, discussing future OEM solutions within both point-of-care diagnostics and cell therapy. As BIO 2024 attracts 20,000+ biotechnology and pharma leaders, thereby offering a fantastic opportunity to identify new opportunities and promising partnerships.

The 2024 BIO International Convention will feature more than 100 interactive sessions across four days covering business development, a variety of diagnostic areas as well as next generation biotherapeutics. The participants in the delegation of the European Pavilion were selected based on their internationalization goals, technological fit with the scope of the trade fair, as well as their capacity to create business out of their participation.

Prior to the convention in San Diego, AcouSort will also participate as part of the Innovation Zone in ISCT 2024 in Vancouver where the company will be showcasing its innovative solutions for automated sample preparation for cell therapy. This well renowned event offers a great opportunity for the company to connect with global scientists, experts and potential customers, making it an ideal platform for AcouSort to continue developing its networking in the field of cell therapy.

“It is with great pride we are going to San Diego as one of only 15 European SMEs or startups selected by EIC for participation at BIO 2024. This is one of the most important conferences in the healthcare and biotech industry, where most leading companies are represented. We are equally excited to participate in the Innovation Zone of ISCT 2024 in Vancouver, which will provide us with a great opportunity to keep extending our reach within the rapidly evolving cell therapy space,” says AcouSort’s CEO Torsten Freltoft.